Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy

Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer

(2017) Emilie Uldry et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy

(2017) Daniel Kraus et al.   MOLECULAR CANCER THERAPEUTICS

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

(2017) Seraina Faes et al.   Oxidative Medicine and Cellular Longevity

The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy

(2016) CA Cummings et al.   CTS-Clinical and Translational Science

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

TORC2 Structure and Function

(2016) Christl Gaubitz et al.   TRENDS IN BIOCHEMICAL SCIENCES

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

(2016) Shona A. Hendry et al.   Frontiers in Immunology

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

(2015) Shaogang Sun et al.   CANCER CELL

Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma

(2015) Bing Zheng et al.   CANCER LETTERS

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804)

(2015) Keith T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors

(2015) Timothy J. Hobday et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of Endothelial Cell Proliferation and Vascular Assembly through Distinct mTORC2 Signaling Pathways

(2015) Shan Wang et al.   MOLECULAR AND CELLULAR BIOLOGY

The Dual mTORC1 and mTORC2 Inhibitor PP242 Shows Strong Antitumor Activity in a Pheochromocytoma PC12 Cell Tumor Model

(2015) Xiaohua Zhang et al.   UROLOGY

T Lymphocyte–Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity

(2015) Christopher V. Carman et al.   Frontiers in Immunology

Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis

(2015) Maikel A. Farhan et al.   PLoS One

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

(2014) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

(2014) N Dey et al.   BRITISH JOURNAL OF CANCER

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2

(2014) Chen Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CD40-Induced Signaling in Human Endothelial Cells Results in mTORC2- and Akt-Dependent Expression of Vascular Endothelial Growth Factor In Vitro and In Vivo

(2014) O. Dormond et al.   JOURNAL OF IMMUNOLOGY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

(2014) Nikhil Wagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3

(2014) K M Dodd et al.   ONCOGENE

Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α

(2014) MIN HUANG et al.   ONCOLOGY REPORTS

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors

(2014) Yoshikazu Kuwahara et al.   Cancer Medicine

Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer

(2013) Liqin Xu et al.   ANTI-CANCER DRUGS

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis

(2013) V Damiano et al.   BRITISH JOURNAL OF CANCER

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma

(2013) Stephen L. Chan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer

(2013) Xian Li et al.   CANCER LETTERS

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

(2013) Y. Pignochino et al.   CLINICAL CANCER RESEARCH

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration

(2013) Chongying Jin et al.   FEBS LETTERS

Rapamycin unbalances the polarization of human macrophages to M1

(2013) Alessia Mercalli et al.   IMMUNOLOGY

Regulation of mTORC1 and its impact on gene expression at a glance

(2013) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells

(2013) Chen Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

(2013) Hao Zhang et al.   PLoS One

Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases

(2013) G. Zhuang et al.   Science Signaling

Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation

(2012) Thomas Walpen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2-mTOR Pathway

(2012) W. Chen et al.   CANCER RESEARCH

SnapShot: Tumor Angiogenesis

(2012) Rakesh K. Jain et al.   CELL

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

(2012) A. Naing et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

(2012) M. A. Davies et al.   CLINICAL CANCER RESEARCH

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Rapamycin-induced tumor vasculature remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation

(2012) Adrianne L. Myers et al.   JOURNAL OF PEDIATRIC SURGERY

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

(2012) Emmanouil Fokas et al.   Radiation Oncology

The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors

(2011) Anne Dormond-Meuwly et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors

(2011) B. L. Falcon et al.   CANCER RESEARCH

Basic and Therapeutic Aspects of Angiogenesis

(2011) Michael Potente et al.   CELL

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

Macrophage regulation of tumor angiogenesis: Implications for cancer therapy

(2011) Mario Leonardo Squadrito et al.   MOLECULAR ASPECTS OF MEDICINE

Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents

(2011) Q. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma

(2011) L. Ellis et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

(2011) A.-C. Piguet et al.   MOLECULAR CANCER THERAPEUTICS

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency

(2011) P. Tandon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

(2011) Marc Dufour et al.   Cancers

Signalling pathways in vasculogenic mimicry

(2010) Yvette W.J. Paulis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma

(2010) Hung Huynh   CANCER

Disrupting established tumor blood vessels

(2010) Mark J. McKeage et al.   CANCER

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

(2010) R. Quek et al.   CLINICAL CANCER RESEARCH

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

Rapamycin Regulates Endothelial Cell Migration through Regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1

(2010) Stephanie C. Moss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma

(2010) John D. Hainsworth et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma

(2010) Li Wang et al.   Journal of Hematology & Oncology

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

MRI with Magnetic Nanoparticles Monitors Downstream Anti-Angiogenic Effects of mTOR Inhibition

(2010) Alexander R. Guimaraes et al.   MOLECULAR IMAGING AND BIOLOGY

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature

(2009) J. D. Murphy et al.   CLINICAL CANCER RESEARCH

Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model

(2009) K. W. Kim et al.   CLINICAL CANCER RESEARCH

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

mTORC2 regulates PGE2-mediated endothelial cell survival and migration

(2008) Shirine Dada et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

(2008) Q. Xue et al.   CANCER RESEARCH

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

(2008) C. R. Schnell et al.   CANCER RESEARCH

In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function

(2008) Amelia Barilli et al.   CARDIOVASCULAR RESEARCH

Combination Strategy Targeting the Hypoxia Inducible Factor-1  with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors

(2008) H. M.W. Verheul et al.   CLINICAL CANCER RESEARCH

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

(2008) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

(2008) Anne-Christine Piguet et al.   JOURNAL OF HEPATOLOGY

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

(2008) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo

(2007) M. SU et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER